# ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

> **NCT00550745** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 11999 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Zoster Vaccine, Live
- **BIOLOGICAL:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00550745
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 11999 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550745, "ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00550745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*